Cargando…
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years
BACKGROUND: Phase 3 clinical studies have shown that long-term treatment with tenofovir disoproxil fumarate (TDF) can suppress hepatitis B viral load and promote significant fibrosis regression and cirrhosis reversal in a majority of treated chronic hepatitis B (CHB) patients. This retrospective ana...
Autores principales: | Buti, Maria, Fung, Scott, Gane, Edward, Afdhal, Nezam H., Flisiak, Robert, Gurel, Selim, Flaherty, John F., Martins, Eduardo B., Yee, Leland J., Dinh, Phillip, Bornstein, Jeffrey D., Mani Subramanian, G., Janssen, Harry L. A., George, Jacob, Marcellin, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387268/ https://www.ncbi.nlm.nih.gov/pubmed/25788199 http://dx.doi.org/10.1007/s12072-015-9614-4 |
Ejemplares similares
-
Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection
por: Buti, Maria, et al.
Publicado: (2014) -
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023) -
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
por: Gordon, Stuart C, et al.
Publicado: (2013) -
Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
por: Ahn, Sang Hoon, et al.
Publicado: (2018) -
Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021)